MRNA Moderna, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1682852 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.1%
TTM net income YoY10.5%
TTM EPS YoY12.7%
Revenue 3-yr CAGR-34.8%
Net income 3-yr CAGR—
Margins
Gross margin28.0%
Operating margin-116.0%
Net margin-110.5%
FCF margin-78.0%
EBITDA margin-106.6%
Returns
ROE-34.5%
ROA-21.8%
ROIC (approx.)-33.4%
Asset turnover0.20x
Leverage & solvency
Liabilities / assets49.2%
Debt / equity0.00x
Current ratio3.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue7.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B |
| Cost of revenue | $868.00M | $1.46B | $4.69B | $5.42B | $2.62B |
| Gross profit | $1.08B | $1.77B | $2.15B | $13.85B | $15.85B |
| R&D expense | $3.13B | $4.54B | $4.84B | $3.29B | $1.99B |
| SG&A expense | $1.02B | $1.17B | $1.55B | $1.13B | $567.00M |
| Operating income | -$3.07B | -$3.94B | -$4.24B | $9.42B | $13.30B |
| Pretax income | -$2.77B | -$3.61B | -$3.94B | $9.57B | $13.29B |
| Income tax | $54.00M | -$46.00M | $772.00M | $1.21B | $1.08B |
| Net income | -$2.82B | -$3.56B | -$4.71B | $8.36B | $12.20B |
| EBITDA | -$2.86B | -$3.76B | -$3.62B | $9.77B | $13.53B |
| EPS (basic) | -7.26 | -9.28 | -12.33 | 21.26 | 30.31 |
| EPS (diluted) | -7.26 | -9.28 | -12.33 | 20.12 | 28.29 |
| Weighted avg. shares (diluted) | 389.00M | 384.00M | 382.00M | 416.00M | 431.00M |
| Balance sheet | |||||
| Cash & equivalents | $2.60B | $1.93B | $2.91B | $3.22B | $6.86B |
| Short-term investments | $3.20B | $5.10B | $5.70B | $6.70B | $3.88B |
| Receivables | $184.00M | $358.00M | $892.00M | $1.39B | $3.17B |
| Inventory | $153.00M | $117.00M | $202.00M | $949.00M | $1.44B |
| Current assets | $6.54B | $8.10B | $10.32B | $13.43B | $16.07B |
| PP&E, net | $2.13B | $2.20B | $1.95B | $2.02B | $1.24B |
| Goodwill | $52.00M | $52.00M | $52.00M | $0 | — |
| Intangibles | $45.00M | $40.00M | $44.00M | $0 | — |
| Total assets | $12.34B | $14.14B | $18.43B | $25.86B | $24.67B |
| Current liabilities | $1.99B | $2.21B | $3.02B | $4.92B | $9.13B |
| Long-term debt | $590.00M | $0 | — | — | — |
| Total debt | $590.00M | $0 | — | — | — |
| Total liabilities | $3.69B | $3.24B | $4.57B | $6.74B | $10.52B |
| Shareholders' equity | $8.65B | $10.90B | $13.85B | $19.12B | $14.14B |
| Net debt | -$2.00B | -$1.93B | — | — | — |
| Shares outstanding | 394.00M | 386.00M | 382.00M | 385.00M | 403.00M |
| Cash flow statement | |||||
| Operating cash flow | -$1.87B | -$3.00B | -$3.12B | $4.98B | $13.62B |
| Capital expenditure | $192.00M | $1.05B | $707.00M | $400.00M | $284.00M |
| Free cash flow | -$2.06B | -$4.05B | -$3.83B | $4.58B | $13.34B |
| Investing cash flow | $1.95B | $1.95B | $4.21B | -$5.18B | -$8.52B |
| Financing cash flow | $593.00M | $56.00M | -$1.38B | -$3.45B | -$873.00M |
| Depreciation & amortization | $211.00M | $185.00M | $617.00M | $348.00M | $232.00M |
| Stock-based compensation | $483.00M | $429.00M | $305.00M | $226.00M | $142.00M |
| Share buybacks | $2.00M | $0 | $1.15B | $3.33B | $857.00M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.